Richard E. Pratley MDSenior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute, Orlando, Florida; Medical Director, AdventHealth Diabetes Institute, Orlando, Florida; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Dr. Richard Pratley, an internationally recognized expert in diabetes, is Senior Investigator and Diabetes Program Lead at the AdventHealth Translational Research Institute and Medical Director of the AdventHealth Diabetes Institute in Orlando, as well as Adjunct Professor of Medicine, Johns Hopkins University School of Medicine.
Dr. Pratley is a principal investigator for both NIH- and pharmaceutical company–sponsored trials in diabetes and obesity. His current research interests include the prevention of diabetes, improving the care of older individuals with diabetes, developing new drugs to treat and prevent diabetes and its complications, understanding the role of the fat cell in increasing the risk for diabetes and heart disease, and investigating extracellular vesicles in inter-cellular and inter-organ cross-talk. He presents his research regularly at national and international meetings and has written over 300 peer-reviewed articles. He is a member of the American Diabetes Association and the European Association for the Study of Diabetes. He has served on the editorial boards of a number of high impact journals, including Diabetes Care, The Lancet Diabetes and Endocrinology, The Journal of Clinical Endocrinology & Metabolism, and the Journal of Diabetes and Its Complications.
After receiving his medical degree from Wayne State University in Detroit and undergoing residency training in internal medicine the University of Michigan in Ann Arbor, he completed fellowships in geriatric medicine and gerontology at the University of Michigan, Johns Hopkins University, and the National Institute on Aging.
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute; Medical Director, AdventHealth Diabetes Institute; Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
MD: Wayne State University, Detroit, Michigan
Fellowship (geriatric medicine and gerontology): University of Michigan, Johns Hopkins University, National Institute on Aging
Prevention of diabetes; improving the care of older individuals with diabetes; developing new drugs to treat and prevent diabetes and its complications; understanding the role of the fat cell in increasing the risk for diabetes and heart disease; investigating extracellular vesicles in inter-cellular and inter-organ cross-talk.
Dr. Pratley has received the following (directed to his institution): speaker fees from Merck and Novo Nordisk; consulting fees from Bayer AG, Endogenex, Inc., Gasherbrum Bio, Inc., Hengrui (USA) Ltd., Intas Pharmaceuticals, Inc., Lilly, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., and Sun Pharmaceutical Industries; and grants from Dompe and Novo Nordisk.
Recent Contributions to PracticeUpdate:
- Cardiovascular Outcomes in Patients With Type 1 and Type 2 Diabetes
- Clinical Inertia: Pharmacist and Primary Care Involvement
- Effects of Tirzepatide vs Insulin Glargine on Kidney Outcomes in Type 2 Diabetes
- Diabetologists and Clinical Inertia
- Clinical Inertia and Patient Engagement
- Clinical Inertia: An Overview
- ADA 2022: Recommendations From Dr. Richard Pratley
- Impact of Closed-Loop Control on Glycemic Metrics in Older Adults With Type 1 Diabetes
- 2021 Top Story in Diabetes: Tirzepatide vs Semaglutide in Patients With Type 2 Diabetes
- Cardiovascular Outcomes With a Novel GLP-1 Receptor Agonist Efpeglenatide in Type 2 DM